The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
复制标题
DOI：
10.1177/2042018815574229
复制
发表时间：
2015-04-01
影响因子：
3.8
通讯作者：
Ahadi, Hamidreza
中科院分区：
文献类型：
--
作者：
Aghamohammadzadeh, Nasser;Niafar, Mitra;Ahadi, Hamidreza
背景：吡格列酮是治疗2型糖尿病（DM）的抗糖尿病药物之一。吡格列酮对血糖、血脂、肝酶和体重的影响已显示出相互矛盾的结果。在这项研究中，我们的目的是评估吡格列酮对糖尿病患者的体重，血脂和肝酶的影响。方法：在这个单臂临床试验中，110例控制不佳的2型糖尿病患者（63.6%女性，平均年龄54.26 +/- 8.96岁）谁是最大剂量的二甲双胍和格列本脲入组。患者接受吡格列酮治疗3个月和实验室检查。于治疗前及治疗结束时检测空腹血糖（FBS）、血红蛋白A1 C（HbA 1C）、胆固醇、甘油三酯、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、碱性磷酸酶（ALK-P）、丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）及体重变化。干预后FBS（p < 0.001）、HbA 1c（p < 0.001）、甘油三酯（p = 0.001）、ALT（p = 0.005）和ALK-P（p = 0.001）水平显著降低，但体重显著增加（p < 0.001）。有胆固醇，低密度脂蛋白和高密度脂蛋白的值没有显着差异，在study.Conclusion：虽然吡格列酮会导致FBS，HbA 1C和甘油三酯水平显着下降，它与体重增加，这将限制其效用。
Background: Pioglitazone is one of the antidiabetic agents used in the management of type 2 diabetes mellitus (DM). The effect of pioglitazone on blood glucose, lipid profile, liver enzymes and weight has been shown with conflicting results. In this study we aim to evaluate the effect of pioglitazone on the weight, lipid profile and liver enzymes in patients with DM.Methods: In this single-arm clinical trial, 110 poorly controlled diabetic type 2 patients (63.6% female with mean age of 54.26 +/- 8.96 years) who were on maximal dosage of metformin and glibenclamide were enrolled. Patients were treated with pioglitazone for 3 months and laboratory. Fasting blood sugar (FBS), haemoglobin A1C (HbA1C), cholesterol, triglyceride, low-density lipoprotein (LDL) and high-density lipoprotein (HDL), alkaline phosphatase (ALK-P), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and weight changes were measured before and at the end of the study.Results: The levels of FBS (p < 0.001), HbA1c (p < 0.001), triglyceride (p = 0.001), ALT (p = 0.005) and ALK-P (p = 0.001) were significantly decreased, but weight was significantly increased (p < 0.001) after the intervention. There were no significant difference in cholesterol, LDL and HDL values before and after study.Conclusion: Although pioglitazone causes a significant decrease in FBS, HbA1C and triglyceride levels, it is associated with weight gain, which would limit its utility.